Caribou Biosciences (CRBU) risk factors, FY2024 10-K

Risks Relating to our Financial Position and Need for Additional Capital

1. 01We have incurred significant operating losses since our inception and anticipate that we will incur continued operating losses for the foreseeable future and we may not be able to achieve or sustain profitability
2. 02We will need substantial additional financing to develop our product candidates and implement our operating plans. If we fail to obtain additional financing, we may be delayed or unable to complete the development and commercialization of our product candidates
3. 03Raising additional capital may cause dilution to our stockholders, restrict our operations, and/or require us to relinquish rights to our technologies or product candidates
4. 04We have a limited operating history, which may make it difficult to evaluate our technologies and product candidate development capabilities or to predict our future performance

Risks Relating to our Business, Government Regulation, Technology, and Industry

1. 05Manufacturing our product candidates is complex and we could experience manufacturing problems during our clinical trials, which could delay or limit commercialization of our product candidates
2. 06Problems in our manufacturing processes could restrict our ability to meet market demand for our products. All these factors could be costly to us and otherwise harm our business, financial condition, results of operations, and prospects
3. 07If we experience delays or difficulties enrolling patients in the clinical trials for our product candidates, our ability to advance our product candidates through clinical development and the regulatory process could be delayed or prevented
4. 08Our clinical trials may fail to adequately demonstrate the safety and efficacy of any of our product candidates and, if this happens, the development of our product candidates may be delayed or unsuccessful, which could prevent or delay regulatory approval and commercialization
5. 09In addition, data obtained from clinical trials are susceptible to varying interpretations, and regulatory agencies may not interpret our data as favorably as we do, which may delay, limit, or prevent regulatory approval
6. 10If our product candidates cause serious adverse events or undesirable side effects, including injury and death, or have other properties that could delay or prevent regulatory approval, they would have limited or no commercial potential
7. 11The FDA or other regulatory agencies may disagree with our regulatory plans and we may fail to obtain regulatory approval of our cell therapy product candidates
8. 12may not be able to commercialize our products, may lose competitive lead time, and our ability to generate revenues will be materially impaired
9. 13If we are required by the FDA to obtain approval of a companion diagnostic in connection with approval of any of our product candidates, and we do not obtain, or face delays in obtaining, FDA approval of the companion diagnostic, we will not be able to commercialize our product candidates
10. 14We may not receive additional priority review, such as RMAT designation, breakthrough therapy designation, or fast track designation, by the FDA for our allogeneic CAR-T cell therapies
11. 15Our allogeneic CAR-T cell therapy product candidates will be regulated as biological products, or biologics, and therefore may be subject to uncertainty regarding regulatory exclusivity or maintaining regulatory approval
12. 16substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved
13. 17We may never obtain approval to commercialize our product candidates outside the United States, which could limit our ability to recognize the full market potential of our product candidates and could materially impair our ability to generate revenues
14. 18Negative public opinion and increased regulatory scrutiny of genetic research and therapies involving genome editing may damage public perception of our product candidates generated through genome editing or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates
15. 19We currently have no marketing and sales organization and as a company have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue
16. 20Our products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers, and others in the medical community, which could significantly harm our business, financial condition, results of operations, and prospects
17. 21Even if we are able to commercialize our product candidates, such products may be subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, which could harm our business
18. 22Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain approval of and commercialize our product candidates and could adversely affect our business
19. 23Our business operations and current and future relationships with clinical site investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties
20. 24We face potential liability related to the privacy of health information we may obtain from the patients in our clinical trials if we fail to comply with privacy laws

Risks Relating to Intellectual Property

1. 25If we do not possess the necessary intellectual property rights covering our CRISPR chRDNA genome-editing technologies, our product candidates, or other proprietary technologies, we may not be able to block competitors or to compete effectively in the market
2. 26Third-party claims of intellectual property infringement may prevent or delay our ability to commercialize our product candidates
3. 27We may not be able to protect our intellectual property rights throughout the world
4. 28We may be subject to claims challenging the inventorship of our patents and other intellectual property
5. 29The terms of our patents may not be sufficient to effectively protect our products and business, and the expiration of our patents may subject us to increased competition
6. 30We may not obtain patent term extension for any product candidates we develop
7. 31Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our genome-editing technologies and product candidates
8. 32We may be involved in lawsuits or other proceedings to enforce or protect our patents, the patents of our licensors, or our other intellectual property rights, which could be expensive, time-consuming, and unsuccessful
9. 33We may not be successful in obtaining or maintaining necessary rights to any future product candidates that we acquire through acquisitions or in-licenses
10. 34Our ability to continue to receive licensing revenue and to enter into new licensing arrangements related to the foundational CRISPR-Cas9 intellectual property will be substantially impaired if such intellectual property is limited by administrative patent proceedings or other patent challenges
11. 35If we are unable to protect the confidentiality of our trade secrets, our business and competitive position will be harmed
12. 36not know whether the steps we have taken to protect our confidential information will be effective. Our trade secrets and other confidential information may be inadvertently or illegally disclosed and competitors may gain access to our trade secrets
13. 37Intellectual property rights do not necessarily address all potential competitive threats and may not adequately protect our business or permit us to maintain our competitive advantage
14. 38If our trademarks are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected

Risks Relating to our Relationships with Third Parties

1. 39cell therapy product candidates, including recently imposed tariffs by the new Administration. Such events could result in a lack of supply for our clinical trials, which could harm our business
2. 40We rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or do not meet deadlines, we may not be able to obtain regulatory approval of, or commercialize, our product candidates
3. 41We may form or seek collaborations or strategic alliances in the future for the development and commercialization of one or more of our product candidates or for new product candidates. We may not be successful in those efforts and, even if we do enter into any collaborations, they may not be successful
4. 42We may not realize the benefits of acquired assets or other strategic transactions

Risks Relating to Employee Matters, Managing Growth, and Other Risks Relating to our Business

1. 43Our future success depends on our ability to retain our executive officers and to attract, retain, and motivate qualified personnel
2. 44We must continue developing and expanding our company, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations
3. 45monitoring and updating as technologies change and efforts to overcome security measures become increasingly sophisticated
4. 46Our employees, clinical trial principal investigators, and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading
5. 47We may be subject to claims that our employees, consultants, or third parties performing services for us have wrongfully used or disclosed confidential information of third parties
6. 48If we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business; additionally, our business could be shut down until we are in compliance with those laws and regulations
7. 49Our insurance policies are expensive and only protect us from some business risks, which may leave us exposed to certain uninsured liabilities
8. 50Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates that we may develop
9. 51As a public company, we are obligated to develop and maintain proper and effective internal controls over financial reporting, and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock
10. 52Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of amounts accrued on our financial statements
11. 53Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited
12. 54Pandemics or other public health crises may adversely impact our business, financial condition, and results of operations, including our preclinical studies and clinical trials, and may cause substantial disruption in the financial markets and adversely impact economies worldwide
13. 55Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses
14. 56Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and our financial condition and results of operations
15. 57We maintain our cash at financial institutions, often in balances that exceed federally insured limits
16. 58Unfavorable global economic conditions could adversely affect our business, financial condition, or results of operations

Risks Relating to Ownership of our Common Stock

1. 59The market price of our common stock has been, and may continue to be, volatile, and our investors may suffer substantial losses if the price of our common stock drops significantly
2. 60Our failure to meet the continued listing requirements of Nasdaq could result in the delisting of our common stock
3. 61We are subject to securities class action litigation, and our officers and directors may be subject to shareholder derivative lawsuits, which may result in substantial costs and a diversion of management's attention and resources, which could harm our business
4. 62If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline
5. 63We are an “emerging growth company” under the JOBS ACT and a “smaller reporting company” and the reduced disclosure requirements and exemptions from certain governance requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors
6. 64We have incurred, and will continue to incur, increased costs as a result of operating as a public company, and our management will continue to devote substantial time to compliance initiatives and corporate governance practices
7. 65We do not expect to pay any dividends for the foreseeable future. Investors may never obtain a return on their investment
8. 66These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock